Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence

키워드

참고문헌 (62)

1. Jung Hoon Lee, "Epidemiology of Heart Failure in Korea: Present and Future", Korean Circulation Journal, 46(5), pp.658~664 (2016), 대한심장학회
2. 최홍미, "Update on heart failure management and future directions", The Korean Journal of Internal Medicine, 34(1), pp.11~43 (2019), 대한내과학회[DOI]
3. Levy D, "Long-term trends in the incidence of and survival with heart failure", N Engl J Med, 347, pp.1397~1402 (2002)
4. McMurray JJ, "Angiotensin-neprilysin inhibition versus enalapril in heart failure", N Engl J Med, 371, pp.993~1004 (2014)
5. Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure : the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)
6. Yancy CW, "2017 ACC", AHA, AHA guideline for the management of heart failure: a report of the American College of Cardiology, pp.American Heart Association task force on clinical practice guidelines and the heart failure society of America, Circulation[DOI]
7. Kim JJ, "Eligibility and usage of sacubitril", valsartan in Korea, 2019, pp.1, 69~71
8. Mann DL, "Mechanisms and models in heart failure : the biomechanical model and beyond", Circulation, 111, pp.2837~2849 (2005)
9. Hartupee J, "Neurohormonal activation in heart failure with reduced ejection fraction", Nat Rev Cardiol, 14, pp.30~38 (2017)
10. Packer M, "The neurohormonal hypothesis : a theory to explain the mechanism of disease progression in heart failure", J Am Coll Cardiol, 20, pp.248~254 (1992)
11. Campbell DJ, "Long-term neprilysin inhibition : implications for ARNIs", Nat Rev Cardiol, 14, pp.171~186 (2017)
12. O’Connor CM, "Effect of nesiritide in patients with acute decompensated heart failure", N Engl J Med, 365, pp.32~43 (2011)
13. Bayes-Genis A, "Neprilysin: indications, expectations, and challenges", Rev Esp Cardiol (Engl Ed), 69, pp.647~649 (2016)
14. Cleland JG, "Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose- ranging Study Investigators", Lancet, 351, pp.1657~1658 (1998)
15. Greenberg B, "Angiotensin receptor-neprilysin inhibition (ARNI) in heart failure", Int J Heart Fail, 2, pp.73~90 (2020)
16. Packer M, "Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)", Circulation, 106, pp.920~926 (2002)
17. Kostis JB, "Omapatrilat and enalapril in patients with hypertension:the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial", Am J Hypertens, 17, pp.103~111 (2004)
18. Nussberger J, "Plasma bradykinin in angio-oedema", Lancet, 351, pp.1693~1697 (1998)
19. McMurray JJ, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure : rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial(PARADIGM-HF)", Eur J Heart Fail, 15, pp.1062~1073 (2013)
20. SOLVD Investigators, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure", N Engl J Med, 325, pp.293~302 (1991)
21. Desai AS, "Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients", Eur Heart J, 36, pp.1990~1997 (2015)
22. Sarrias A, "Is sacubitril", valsartan(also)an antiarrhythmic drug, 2018, pp.138, 551~553
23. Chang PC, "LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model", Cardiovasc Ther, 2019, pp.6032631~ (2019)
24. Packer M, "Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure", Circulation, 131, pp.54~61 (2015)
25. Gheorghiade M, "Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure", JAMA, 296, pp.2217~2226 (2006)
26. Bohm M, "Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril", valsartan(LCZ696)in patients with chronic heart failure and reduced ejection fraction : results from PARADIGM-HF, 2017, pp.38, 1132~1143
27. Senni M, "Initiating sacubitril", valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens, 2016, pp.18, 1193~1202
28. Senni M, "Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril", valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study, 2018, pp.20, 491~500
29. Velazquez EJ, "Angiotensin-neprilysin inhibition in acute decompensated heart failure", N Engl J Med, 380, pp.539~548 (2019)
30. Morrow DA, "Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril", valsartan or enalapril in the PIONEER-HF trial, 2019, pp.139, 2285~2288
31. Velazquez EJ, "Rationale and design of the comParIson Of sacubitril", valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode(PIONEER-HF)trial, 2018, pp.198, 145~151
32. DeVore AD, "Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure : secondary analysis of the open-label extension of the PIONEER-HF trial", JAMA Cardiol, 5, pp.202~207 (2019)
33. Morrow DA, "Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial", Eur Heart J, 40, pp.3345~3352 (2019)
34. Wachter R, "Initiation of sacubitril", valsartan in haemodynamically stabilized heart failure patients in hospital or early after discharge : primary results of the randomised TRANSITION study, 2019, pp.21, 998~1007
35. Senni M, "Initiation of sacubitril", valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed(de novo)heart failure : a subgroup analysis of the TRANSITION study, 2020, pp.22, 303~312
36. Solomon SD, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction : a phase 2 double-blind randomised controlled trial", Lancet, 380, pp.1387~1395 (2012)
37. Solomon SD, "Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction : rationale and design of the PARAGON-HF trial", JACC Heart Fail, 5, pp.471~482 (2017)
38. Solomon SD, "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction", N Engl J Med, 381, pp.1609~1620 (2019)
39. Shah SJ, "Phenomapping for novel classification of heart failure with preserved ejection fraction", Circulation, 131, pp.269~279 (2015)
40. Shah AM, "Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction", J Am Coll Cardiol, 74, pp.2858~2873 (2019)
41. O’Connor CM, "PARAGON-HF : why we do randomized, controlled clinical trials", N Engl J Med, 381, pp.1675~1676 (2019)
42. Kang SH, "Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF", Heart, 101, pp.1881~1888 (2015)
43. Lyle MA, "Circulating neprilysin in patients with heart failure and preserved ejection fraction", JACC Heart Fail, 8, pp.70~80 (2020)
44. McMurray JJV, "Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction : insights from PARAGON-HF", Circulation, 141, pp.338~351 (2020)
45. Solomon SD, "Sacubitril", valsartan across the spectrum of ejection fraction in heart failure, 2020, pp.141, 352~361
46. Kramer DG, "Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction : a meta-analytic approach", J Am Coll Cardiol, 56, pp.392~406 (2010)
47. Wang Y, "Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling : meta-analysis", J Am Heart Assoc, 8, pp.e012272~ (2019)
48. Januzzi JL Jr, "Association of change in n-terminal pro-b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction", JAMA, 322, pp.1~11 (2019)
49. Kang DH, "Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation", Circulation, 139, pp.1354~1365 (2019)
50. Williams B, "Effects of sacubitril", valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension : the PARAMETER study, 2017, pp.69, 411~420
51. Desai AS, "Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction : a randomized clinical trial", JAMA, 322, pp.1~10 (2019)
52. Damman K, "Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure", JACC Heart Fail, 6, pp.489~498 (2018)
53. Voors AA, "Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction", Eur J Heart Fail, 17, pp.510~517 (2015)
54. Packer M, "Effect of neprilysin inhibition on renal function in patients with type 2diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system:a secondary analysis of the PARADIGM-HF trial", Lancet Diabetes Endocrinol, 6, pp.547~554 (2018)
55. Mullens W, "Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure", JACC Heart Fail, 6, pp.499~502 (2018)
56. Haynes R, "Effects of sacubitril", valsartan versus irbesartan in patients with chronic kidney disease, 2018, pp.138, 1505~1514
57. Seferovic JP, "Effect of sacubitril", valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes : a post-hoc analysis from the PARADIGM-HF trial, 2017, pp.5, 333~340
58. Kim KJ, "Focused update of 2016Korean Society of Heart Failure guidelines for the management of chronic heart failure", Int J Heart Fail, 1, pp.4~24 (2019)
59. Seferovic PM, "Clinical practice update on heart failure 2019 : pharmacotherapy, procedures, devices and patient management : an expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology", Eur J Heart Fail, 21, pp.1169~1186 (2019)
60. Hollenberg SM, "2019ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure : a report of the American college of Cardiology solution set oversight committee", J Am Coll Cardiol, 74, pp.1966~2011 (2019)
61. Oh J, "Real-world eligibility for sacubitril", valsartan in heart failure with reduced ejection fraction patients in Korea: data from the Korean Acute Heart Failure (KorAHF) Registry, 2019, pp.1, 57~68
62. Cannon JA, "Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction", Eur J Heart Fail, 19, pp.129~137 (2017)

관련 논문AI추천